# Amal Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amal-therapeutics

- Industry: Biotechnology
- Headquarters: Geneva, Switzerland
- Website: www.amaltherapeutics.com
- Total disclosed funding: $37M
- Latest round: Series B (Nov 12, 2018)
- Investors on record: 6

## About

Amal Therapeutics SA is a biotechnology company focused on developing advanced therapeutic vaccines that enhance cancer treatment through its proprietary KISIMA® platform.Founded in 2012 and headquartered in Geneva, Switzerland, Amal Therapeutics SA specializes in the development of therapeutic vaccines. The company has undergone significant strategic developments, including a Trade Sale in July 2019, when Boehringer Ingelheim International GmbH acquired it for up to EUR 325 million. Laetitia Devy-Dimanche serves as the CEO, leading the company's innovative approaches in oncology, and overseeing a total of 5 deals since inception.Amal Therapeutics specializes in developing innovative therapeutic vaccines aimed at enhancing cancer treatment through its proprietary immunization platform, KISIMA®. This platform is designed to stimulate the immune system by delivering multiple antigens within a single vaccine, thereby providing a comprehensive approach to cancer therapy. The company's lead product, ATP128, is a therapeutic vaccine specifically targeting metastatic colorectal cancers, a significant health challenge worldwide. Amal Therapeutics serves oncology-focused healthcare providers, research institutions, and pharmaceutical partners primarily in Europe and the United States, focusing on markets where there is a critical need for effective cancer therapies. The KISIMA® platform's self-adjuvanting technology enables it to offer a novel solution for patients, highlighting the company's commitment to transforming cancer treatment prospects.Amal Therapeutics generates revenue through strategic partnerships and collaborations within the pharmaceutical and biotechnology sectors. The company engages in B2B transactions, primarily collaborating with larger pharmaceutical firms to co-develop and distribute its therapeutic vaccines. Revenue structures may include milestone payments and royalties based on the success of product development and commercialization efforts. The flagship product, ATP128, plays a crucial role in these transactions, as it represents a significant advancement in cancer therapy and is likely central to partnership agreements. The company’s developmental focus and alliances with industry leaders position it to capitalize on licensing opportunities and collaborative research funding, ensuring a robust framework for revenue generation without the reliance on direct consumer sales.Going forward, Amal Therapeutics is focused on expanding its product portfolio with new therapeutic vaccines, leveraging its KISIMA® platform. The company is also targeting expansion into new markets, particularly in North America and Asia, by 2022. The recent Trade Sale finalized on July 15, 2019, with Boehringer Ingelheim International GmbH, provides significant financial backing of up to EUR 325 million to support ongoing research and development of its products and facilitate market entry initiatives.

## Funding rounds

- Series B, Nov 12, 2018, $24M — Schroders Capital, BioMed Partners, Boehringer Ingelheim Venture, High-Tech Gruenderfonds, Vi Partners, 3B Future Health Fund
- Series B, Sep 5, 2017, $9.7M — Schroders Capital, BioMed Partners, Boehringer Ingelheim Venture, High-Tech Gruenderfonds, Vi Partners, 3B Future Health Fund
- Series A, Mar 30, 2016, $3M — Boehringer Ingelheim Venture, High-Tech Gruenderfonds, Vi Partners
- Seed, Feb 21, 2014 — Boehringer Ingelheim Venture, High-Tech Gruenderfonds

## Investors

- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Seed, Series A, Series B
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series A, Series B
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series A, Series B
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series B
- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Series B